This is a review about p53, based on 210 published articles (read how Labome selects the articles), using p53 antibody in all methods. It is aimed to help Labome visitors find the most suited p53 antibody.
p53 synonym: BCC7; LFS1; P53; TRP53; antigen NY-CO-13; cellular tumor antigen p53; p53 tumor suppressor; phosphoprotein p53; transformation-related protein 53

gallery
Santa Cruz BiotechnologySanta Cruz Biotechnology p53 product
  • ChIP assayIn 2012, In Hye Lee et al. employed Santa Cruz Biotechnology p53 antibody to perform western blot and ChIP in order to show that p53-dependent cell proliferation and survival could be regulated by atg7 [ncbi , more ]. In 2010, David Bungard et al. employed Santa Cruz Biotechnology p53 antibody to carry out ChIP assays in order to investigate the mechanism for AMP-activated protein kinase regulating cellular responses to metabolic stress (catalog: sc-100) [ncbi , more ]. In 2005, Shashirekha Shetty et al. applied Santa Cruz Biotechnology p53 antibody to investigate the regulation of death receptor 5 expression by NFKB1 [ncbi , more ]. Gina Fusaro et al. used Santa Cruz Biotechnology p53 antibody to study p53 in T47D cells or MCF7 breast carcinoma cells [ncbi , more ] in 2003 and Daniel J Freeman et al. used Santa Cruz Biotechnology p53 antibody to study the regulation of p53 protein levels and activity by PTEN tumor suppressor through phosphatase-dependent and independent mechanisms [ncbi , more ].
  • ELISAIn 2005, Armando Rivera et al. employed Santa Cruz Biotechnology p53 antibody to study the p53-induced Gene-6 (proline oxidase) which mediates apoptosis through a calcineurin-dependent pathway [ncbi , more ].
  • EMSAIn 2001, T Imamura et al. utilized Santa Cruz Biotechnology p53 antibody to study the effect of interaction of p53 with HMG1 after DNA damage on HMG1 binding to Cisplatin-modified DNA [ncbi , more ]. In 2000, M Pastorcic et al. utilized Santa Cruz Biotechnology p53 antibody to study the regulation of transcription of the human presenilin-1 gene by Ets rranscription factors and the p53 protooncogene [ncbi , more ].
  • flow cytometryIn 2002, Ethan A Kohn et al. applied Santa Cruz Biotechnology p53 antibody to study the role of UCN-01 in checkpoint regulation [ncbi , more ].
  • immunocytochemistryIn 2011, Aniek Janssen et al. used Santa Cruz Biotechnology p53 antibody to perform western blot and immunocytochemistry in order to show that chromosomal structural aberrations could be caused by chromosome segregation errors [ncbi , more ]. Thérèse Rachell Theodoro et al. used Santa Cruz Biotechnology p53 antibody to demonstrate that heparanase was expressed in lymphocytes of breast cancer PBMC [ncbi , more ] in 2007 and Pabbisetty Sudheer Kumar et al. used Santa Cruz Biotechnology p53 antibody to study the role for p21cip/waf1 and p27kip1 in TNF-alpha-induced inhibition of proliferation in human glioma cells [ncbi , more ]. Roman Kulikov et al. employed Santa Cruz Biotechnology p53 antibody to investigate the regulation of p53 by GSK through MDM2 [ncbi , more ] in 2005 and Andrea Mueller et al. used Santa Cruz Biotechnology p53 antibody to study the interaction between calcium-binding protein S100A2 and p53 [ncbi , more ]. Lisa Y Zhao et al. utilized Santa Cruz Biotechnology p53 antibody to study the inetraction between Daxx and E1B 55-kDa protein [ncbi , more ] in 2003 and Heng Yin Yang et al. used Santa Cruz Biotechnology p53 antibody to study the effect of 14-3-3 on p53 and tumor growth [ncbi , more ]. In 2002, Philip J Young et al. used Santa Cruz Biotechnology p53 antibody to investigate the interaction between SMN1 and p53 [ncbi , more ].
  • immunohistochemistryIn 2009, Wei Qin Jiang et al. utilized Santa Cruz Biotechnology p53 antibody to perform western blot and immunohistochemistry in order to study the function of HP1 proteins in the alternative lengthening of telomeres-associated PML bodies by p53/p21 [ncbi , more ]. In 2007, Douglas M Iddings et al. applied Santa Cruz Biotechnology p53 antibody to study the relationship between angiogenesis markers with lymph node metastasis in early colorectal cancer in paraffin sections from human tumor [ncbi , more ]. In 2005, Andrea Mueller et al. used Santa Cruz Biotechnology p53 antibody to study the interaction between calcium-binding protein S100A2 and p53 [ncbi , more ]. In 2004, Barbara I Oberschmid et al. used Santa Cruz Biotechnology p53 antibody to study expression of secreted frizzled receptor protein 1 in patients with hyperplastic polyposis coli syndrome. [ncbi , more ]. Gina Fusaro et al. used Santa Cruz Biotechnology p53 antibody to study p53 in T47D cells or MCF7 breast carcinoma cells [ncbi , more ] in 2003 and Anna A Sablina et al. used Santa Cruz Biotechnology p53 antibody to study the roles for tumor suppressor p53 and its homologue p73 in cell migration [ncbi , more ]. In 2002, Virginia Urquidi et al. used Santa Cruz Biotechnology p53 antibody to study the associativity of expression of thrombospondin-1 and osteopontin with absence or presence metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis [ncbi , more ]. In 2001, J Wang et al. used Santa Cruz Biotechnology p53 antibody to study the effect of mtDNA loss and respiratory chain function deficiency on apoptosis in vivo [ncbi , more ].
  • immunoprecipitationIn 2009, Jennifer Hein et al. employed Santa Cruz Biotechnology p53 antibody to study the effect of simian virus 40 large T antigen on genome integrity and DNA damage response [ncbi , more ]. In 2008, Sanjeev Shangary et al. utilized Santa Cruz Biotechnology p53 antibody to study the mechanism and effect of p53 activation by a potent and specific MDM2 antagonist (MI-43) in colon cancer [ncbi , more ]. In 2006, Jianwei Ren et al. applied Santa Cruz Biotechnology p53 antibody to study the role for FAT10 in the regulation of chromosomal stability [ncbi , more ]. Roman Kulikov et al. employed Santa Cruz Biotechnology p53 antibody to investigate the regulation of p53 by GSK through MDM2 [ncbi , more ] in 2005 and Andrea Mueller et al. used Santa Cruz Biotechnology p53 antibody to study the interaction between calcium-binding protein S100A2 and p53 [ncbi , more ]. Santa Cruz Biotechnology p53 antibody was utilized in 2003 to detect p53 expression in 786-O, UOK121, and UMRC6 renal cell carcinoma (RCC) cells [ncbi , more ], to study the role for HuR in binding to the p53 mRNA and enhancing its translation [ncbi , more ]and to study the effect of 14-3-3 on p53 and tumor growth [ncbi , more ]. David M Keller et al. used Santa Cruz Biotechnology p53 antibody to study the role of p53 serine 392 phosphorylation in induction of the assembly of the CK2 hSPT16 SSRP1 complex after UV [ncbi , more ] in 2002 and Xiaodan Yu et al. used Santa Cruz Biotechnology p53 antibody to study expression of p53, ErbB1, ErbB2, and Raf-1 in lung cancer [ncbi , more ]. In 2001, T Imamura et al. utilized Santa Cruz Biotechnology p53 antibody to study the effect of interaction of p53 with HMG1 after DNA damage on HMG1 binding to Cisplatin-modified DNA [ncbi , more ]. In 2000, S Nakamura et al. used Santa Cruz Biotechnology p53 antibody to investigate the effect of multiple lysine mutations in the C-terminal domain of p53 on MDM2-dependent protein degradation and ubiquitination [ncbi , more ].
  • western blotJeremy E Purvis et al. applied Santa Cruz Biotechnology p53 antibody to perform western blot in order to show that cell fate was regulated by p53 dynamics [ncbi , more ] in 2012 and In Hye Lee et al. used Santa Cruz Biotechnology p53 antibody to perform western blot and ChIP in order to show that p53-dependent cell proliferation and survival could be regulated by atg7 [ncbi , more ]. In 2011, Aniek Janssen et al. used Santa Cruz Biotechnology p53 antibody to perform western blot and immunocytochemistry in order to show that chromosomal structural aberrations could be caused by chromosome segregation errors [ncbi , more ]. Santa Cruz Biotechnology p53 antibody was applied in 2010 to perform western blot in order to study the relation between Drosophila p53 and the human p53 network [ncbi , more ], to investigate the role of TGFB1 in the regulation of Mdm2 expression and late-stage breast cancer metastasis [ncbi , more ], to investigate the role of DJ-1 mutations in the regulation of Parkinson disease pathology [ncbi , more ], to investigate the role of hnRNPK in pancreatic cancer [ncbi , more ]and to study the effect of the candidate tumor suppressor gene ECRG4 on cancer cells migration and invasion in esophageal carcinoma [ncbi , more ]. Santa Cruz Biotechnology p53 antibody was employed in 2009 to perform western blot and immunohistochemistry in order to study the function of HP1 proteins in the alternative lengthening of telomeres-associated PML bodies by p53/p21 [ncbi , more ], to investigate the role of ARIA in the regulation of endothelial apoptosis and angiogenesis [ncbi , more ], to perform western blot in order to show that the absence of p53 can result in tumourgenesis in those mesenchymal stem cells lacking p21 [ncbi , more ], to investigate the role of hypoxia in the regulation of human lung fibroblast proliferation [ncbi , more ], to investigate the role of Aurora B in the regulation of postmitotic endoreduplication checkpoint [ncbi , more ], to show that the cancer cells with inactivated p53 were highly sensitive to PLK1 inhibitors [ncbi , more ], to perform western blot in order to prove that the catalytic activity of IKK modified with O-GlcNAc in p53-deficient cells is enhanced [ncbi , more ], to detect p53 in western blot in order to find out the novel mechanism by which eIF4E levels are regulated at the level of mRNA stability [ncbi , more ], to perform western blot in order to study the function of beta-catenin in mediating the effects of ionizing radiation in fibroblasts [ncbi , more ], to study the role for Hsp72 in suppression of the oncogene-induced senescence [ncbi , more ], to study the effect of simian virus 40 large T antigen on genome integrity and DNA damage response [ncbi , more ]and to perform western blot in order to investigate the relations between SIK1 and anoikis, metastasis [ncbi , more ]. Santa Cruz Biotechnology p53 antibody was applied in 2008 to examine the effects of combining a proteasome inhibitor with an HDAC inhibitor in GBM cell lines [ncbi , more ], to perform western blot in order to study the contribution of hSRBC epigenetic inactivation to the malignant progression in gastric cancer through attenuated p53 response to stresses [ncbi , more ]and to perform western blot in order to show that mTOR is identified as a regulator of p73 by a gene signature-based approach [ncbi , more ]. Santa Cruz Biotechnology p53 antibody was used in 2007 to report an increase in S100A6 protein level in colon and lung cancer cells postexposure to ionizing radiation [ncbi , more ], to investigate the role of these complexes in the biology of mesenchymal stem cells (MSCs) [ncbi , more ], to study the role of MEG3 in tumor suppression [ncbi , more ], to perform western blot in order to study the dependency on oxidative phosphorylation during transformation of human mesenchymal stem cells (catalog: sc-126) [ncbi , more ], to identify p18 (Hamlet) as a new cell-fate regulator [ncbi , more ], to study the association between maspin expression with distinct clinicopathological parameters and TP53 expression in a representative series of primary non-small cell lung cancer (NSCLC) [ncbi , more ]and to perform western blot in order to show that global sumoylation and Pias3 stabilization could be regulated by nitric oxide [ncbi , more , fig ]. Laura M Rozan et al. utilized Santa Cruz Biotechnology p53 antibody to identify Traf4 interacting proteins [ncbi , more ] in 2006 and Sylwia Ammoun et al. used Santa Cruz Biotechnology p53 antibody to study the role of G-protein-coupled receptor signaling in cell death via p38 mitogen-/stress-activated protein kinase independent of p53 and caspase activation [ncbi , more ]. Santa Cruz Biotechnology p53 antibody was employed in 2005 to investigate the regulation of Cdc6 protein stability by p53 [ncbi , more ], to investigate the decrease of COX-2 Levels through p53 and NFkB by T-oligo [ncbi , more ], to investigate the regulation of death receptor 5 expression by NFKB1 [ncbi , more ], to study the induction of neuroblastoma cell apoptosis by TrkA [ncbi , more ], to study the interaction between calcium-binding protein S100A2 and p53 [ncbi , more ], to study the p53-induced Gene-6 (proline oxidase) which mediates apoptosis through a calcineurin-dependent pathway [ncbi , more ], to study the apoptosis in p53-defective tumors [ncbi , more ], to study the effect of human p53 serine 46 phosphorylation on promoter selection and apoptosis [ncbi , more ], to study p130/p107/p105Rb-dependent transcriptional repression during DNA-damage-induced cell-cycle exit at G2 [ncbi , more ], to demonstrate that 15-PGDH induce apoptosis and function like a tumor suppressor [ncbi , more ]and to investigate the regulation of p53 by GSK through MDM2 [ncbi , more ]. Santa Cruz Biotechnology p53 antibody was applied in 2004 to study the regulation of human Rif1, ortholog of a yeast telomeric protein, by ATM and 53BP1 and its function in the S-phase checkpoint [ncbi , more ], to study the effect of p53-independent NOXA induction on apoptotic resistance of malignant melanomas [ncbi , more ], to study GCP in vitro and in vivo for potential utility as a prostate cancer chemopreventative agent in human prostate cancer cell line [ncbi , more ], to study the replicative senescence triggered by DNA damage checkpoint kinase Chk2 [ncbi , more ], to study the effec of activated m-Calpain on chromosome alignment on the metaphase plate during mitosis [ncbi , more ]and to study the taxol-induced caspase-10-dependent apoptosis [ncbi , more ]. Santa Cruz Biotechnology p53 antibody was applied in 2003 to detect p53 expression in 786-O, UOK121, and UMRC6 renal cell carcinoma (RCC) cells [ncbi , more ], to study p53 in T47D cells or MCF7 breast carcinoma cells [ncbi , more ], to study the role for HuR in binding to the p53 mRNA and enhancing its translation [ncbi , more ], to study the role of AMF/PGI in the regulation of cell proliferation [ncbi , more ], to study the roles for tumor suppressor p53 and its homologue p73 in cell migration [ncbi , more ], to study a physiological role of hGTSE-1 in apoptosis control after DNA damage during S and G2 phases through regulation of p53 function. [ncbi , more ], to detect p53 in the HCT116 cell transfected with RET/PTC3 [ncbi , more ], to 1:1000 to facilitate the establishment of an in vitro model that can be reliably used to study the pathogenesis of MCL [ncbi , more ], to study the regulation of p53 protein levels and activity by PTEN tumor suppressor through phosphatase-dependent and independent mechanisms [ncbi , more ], to study the direct interactions between HIF-1 alpha and Mdm2 in modulating p53 function [ncbi , more ], to study the role of proline oxidase in renal carcinomas [ncbi , more ]and to study the effect of 14-3-3 on p53 and tumor growth [ncbi , more ]. Santa Cruz Biotechnology p53 antibody was employed in 2002 to study the role of p53 serine 392 phosphorylation in induction of the assembly of the CK2 hSPT16 SSRP1 complex after UV [ncbi , more ], to study the stress-dependent nucleolin mobilization mediated by p53-nucleolin complex formation [ncbi , more ], to study the effects of UVB irradiation on cell cycle and apoptosis markers [ncbi , more ], to show that Mdm2 inhibition of p53 induces E2F1 transactivation via p21 [ncbi , more ], to study the role of Tbx3 in p53 pathway [ncbi , more ], to study the effects of NaB on IGFBP-3 expression in human prostate cancer cell lines [ncbi , more ], to study expression of p53, ErbB1, ErbB2, and Raf-1 in lung cancer [ncbi , more ], to study the mechanism by which WISP-1 promotes tumorigenicity [ncbi , more ], to study the differences of effects of ik3-1/cables on p53- and p73-induced cell death [ncbi , more ], to investigate the interaction between SMN1 and p53 [ncbi , more ]and to study the role of polymerase eta and p53 in cell survival, apoptosis and Mre11 recombination during S phase checkpoint arrest after UV irradiation [ncbi , more ]. Santa Cruz Biotechnology p53 antibody was applied in 2001 to study the linkage between TMZ exposure and the activation of the G2 checkpoint [ncbi , more ], to study the reactive oxygen species-induced phosphorylation of p53 on serine 20 partially mediated by polo-like kinase-3 [ncbi , more ], to study the effect of mtDNA loss and respiratory chain function deficiency on apoptosis in vivo [ncbi , more ], to study the effect of interaction of p53 with HMG1 after DNA damage on HMG1 binding to Cisplatin-modified DNA [ncbi , more ]and to study the function of hSIR2 (SIRT1) as an NAD-dependent p53 deacetylase [ncbi , more ]. Santa Cruz Biotechnology p53 antibody was utilized in 2000 to study the effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin [ncbi , more ], to study the regulation of transcription of the human presenilin-1 gene by Ets rranscription factors and the p53 protooncogene [ncbi , more ]and to investigate the effect of multiple lysine mutations in the C-terminal domain of p53 on MDM2-dependent protein degradation and ubiquitination [ncbi , more ].
Cell Signaling TechnologyCell Signaling Technology p53 product
  • immunocytochemistryIn 2011, Aniek Janssen et al. utilized Cell Signaling Technology p53 antibody to perform immunocytochemistry in order to show that chromosomal structural aberrations could be caused by chromosome segregation errors [ncbi , more ]. In 2005, Noriko Shirata et al. applied Cell Signaling Technology p53 antibody to investigate the induction of DNA damage checkpoint signal transduction by herpes simplex virus [ncbi , more ]. In 2001, M Castedo et al. used Cell Signaling Technology p53 antibody to study the role of phosphorylation of p53S15 by mTOR/FRAP in syncytial apoptosis driven by HIV-1 Env [ncbi , more ].
  • immunohistochemistryIn 2010, Jay P Reddy et al. applied Cell Signaling Technology p53 antibody to show the importance of protection of the ATM-mediated DDR-p53 signaling pathway for breast cancer prevention [ncbi , more ]. Jung Yoon Park et al. utilized Cell Signaling Technology p53 antibody to study the molecular basis of the mutant-specific manifestation of age-related phenotypes [ncbi , more ] in 2008 and Suchismita Panda et al. used Cell Signaling Technology p53 antibody to show in vivo accumulation of cells without extremes in enrichment or modification of many of the DDR proteins related to senescence [ncbi , more ]. In 2005, Vaneeta Marwaha et al. used Cell Signaling Technology p53 antibody to study the down-regulation of constitutive and UVB-induced COX-2 levels by T-oligo treatment through p53- and NFkappaB-dependent repression of the COX-2 promoter [ncbi , more ].
  • immunoprecipitationIn 2002, Yaron Daniely et al. applied Cell Signaling Technology p53 antibody to study the role of p53-nucleolin complex to mediate stress-dependent nucleolin mobilization [ncbi , more ]. In 2001, M Castedo et al. used Cell Signaling Technology p53 antibody to study the role of phosphorylation of p53S15 by mTOR/FRAP in syncytial apoptosis driven by HIV-1 Env [ncbi , more ].
  • western blotIn 2012, In Hye Lee et al. used Cell Signaling Technology p53 antibody to perform western blot in order to show that p53-dependent cell proliferation and survival could be regulated by atg7 [ncbi , more ]. Hui Kuan Lin et al. employed Cell Signaling Technology p53 antibody to perform western blot in order to clarify that Skp2 involved in the p19Arf-p53 pathway independent cellular senescence [ncbi , more ] in 2010 and Ying Geng et al. used Cell Signaling Technology p53 antibody to investigate the role for activated Bax in the regulation of p53-dependent, transcription-independent neural precursor cell apoptosis [ncbi , more ]. Cell Signaling Technology p53 antibody was utilized in 2009 to study the effect of MDM2-dependent inhibition of p53 on EBV growth transformation of B-cell and infected-cell survival [ncbi , more ], to determine the effect of HMGN1 for ATM activation by regulating the levels of histone modifications [ncbi , more ], to detect p53 in western blot in order to demonstrate that the MAPK/CREB cascade and the STAT-3 signaling pathway mediate H-IL-6-activated neurogenesis and gliogenesis [ncbi , more ], to study the role of TRAIL for activation of DNA damage response pathways with histone H2AX and Chk2 phosphorylations [ncbi , more ], to study the effect of simian virus 40 large T antigen on genome integrity and DNA damage response [ncbi , more ]and to perform western blot in order to investigate the relations between SGI-1776 and chronic lymphocytic leukemia [ncbi , more ]. Cell Signaling Technology p53 antibody was utilized in 2008 to demonstrate that ATM undergoes an activating phosphorylation in syncytia elicited by the envelope glycoprotein complex (Env) of human immunodeficiency virus-1 (HIV-1) in vitro [ncbi , more ], to study the role for saturated fatty acids in DNA damage response [ncbi , more ], to perform western blot in order to study how genistein regulate tumor suppressor genes in prostate cancer cells [ncbi , more ], to study the antiapoptotic role of PXR in colon cancer [ncbi , more ], to perform western blot in order to study the contribution of hSRBC epigenetic inactivation to the malignant progression in gastric cancer through attenuated p53 response to stresses [ncbi , more ]and to study the mechanism and effect of p53 activation by a potent and specific MDM2 antagonist (MI-43) in colon cancer [ncbi , more ]. Cell Signaling Technology p53 antibody was applied in 2007 to report an increase in S100A6 protein level in colon and lung cancer cells postexposure to ionizing radiation [ncbi , more ], to identify p18 (Hamlet) as a new cell-fate regulator [ncbi , more ]and to study the molecular mechanisms of BAF53 in regulating p53-mediated gene transcription [ncbi , more ]. Cell Signaling Technology p53 antibody was applied in 2005 to investigate the induction of DNA damage checkpoint signal transduction by herpes simplex virus [ncbi , more ], to investigate the role of ORC2 in CDK2 activation [ncbi , more ], to study the effect of human p53 serine 46 phosphorylation on promoter selection and apoptosis [ncbi , more ], to study the prolongation of life span of human umbilical cord blood-derived mesenchymal stem cells (UCBMSCs) [ncbi , more ]and to study the down-regulation of constitutive and UVB-induced COX-2 levels by T-oligo treatment through p53- and NFkappaB-dependent repression of the COX-2 promoter [ncbi , more ]. Cell Signaling Technology p53 antibody was used in 2004 to study the regulation of human Rif1, ortholog of a yeast telomeric protein by ATM and 53BP1 and its function in the S-phase checkpoint [ncbi , more ], to study the role of disialoganglioside (GD3) synthase gene to suppress vascular smooth muscle cell (VSMC) responses via the inhibition of ERK1/2 phosphorylation, cell cycle progression, and matrix metalloproteinase-9 expression [ncbi , more ]and to study the effect of human PTIP on ATM-mediated activation of p53 and cellular resistance to ionizing radiation [ncbi , more ]. Cell Signaling Technology p53 antibody was utilized in 2003 to determine whether Nrf1 and Nrf2 have overlapping functions during early development and in the oxidative stress response [ncbi , more ], to study the role of the promyelocytic leukemia protein to protect p53 from Mdm2-mediated inhibition and degradation [ncbi , more ], to study the role of p53 to repress cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1 [ncbi , more ], to study that resveratrol increases serine15-phosphorylated but transcriptionally impaired p53 and induces a reversible DNA replication block in serum-activated vascular smooth muscle cells [ncbi , more ], to study the role of phosphorylation and hsp90 binding in stabilizing p53 after heat shock [ncbi , more ]and to study the role of MED1 in DNA damage response [ncbi , more ]. In 2002, Xiaodan Yu et al. applied Cell Signaling Technology p53 antibody to study the modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228 [ncbi , more ]. M Castedo et al. used Cell Signaling Technology p53 antibody to study the role of phosphorylation of p53S15 by mTOR/FRAP in syncytial apoptosis driven by HIV-1 Env [ncbi , more ] in 2001 and S Xie et al. used Cell Signaling Technology p53 antibody to investigate oxidative stress-induced activation of p53 partially mediated by Plk3 [ncbi , more ]. In 2000, D L Persons et al. applied Cell Signaling Technology p53 antibody to show the effect of cisplatin, PD98059, SB202190, wortmannin, and caffeine on the phosphorylation level of p53 protein at serine 15 [ncbi , more ].
EMD MilliporeEMD Millipore p53 product
  • EMSAIn 2003, Maoxiang Li et al. applied EMD Millipore p53 antibody to study the phosphatase MKP1 as a transcriptional target of p53 involved in cell cycle regulation [ncbi , more ]. In 2001, T Imamura et al. employed EMD Millipore p53 antibody to study the role of the interaction of p53 with HMG1 after DNA damage to enhance binding of cisplatin-modified DNA to high mobility group 1 protein [ncbi , more ]. In 2000, S Nakamura et al. applied EMD Millipore p53 antibody to study the effect of multiple lysine mutations in the C-terminal domain of p53 on MDM2-dependent protein degradation and ubiquitination [ncbi , more ].
  • immunocytochemistryRoman Kulikov et al. applied EMD Millipore p53 antibody to study the regulation of p53 abundance through glycogen synthase kinase 3-dependent phosphorylation of Mdm2 [ncbi , more ] in 2005 and Noriko Shirata et al. used EMD Millipore p53 antibody to investigate the induction of DNA damage checkpoint signal transduction by herpes simplex virus [ncbi , more ]. In 2004, Zhihui Feng et al. employed EMD Millipore p53 antibody to study the induction of p53-dependent BRCA1 nuclear export by DNA damage [ncbi , more ]. In 2002, Setha Douc-Rasy et al. applied EMD Millipore p53 antibody to study the role for the p73 gene in human neuroblastic tumors [ncbi , more ]. In 2000, S Nakamura et al. applied EMD Millipore p53 antibody to study the effect of multiple lysine mutations in the C-terminal domain of p53 on MDM2-dependent protein degradation and ubiquitination [ncbi , more ].
  • immunohistochemistryEMD Millipore p53 antibody was utilized in 2003 to study the role of TIMP-2 in human urothelial cancer [ncbi , more ], to study p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme [ncbi , more ], to study the correlation of the expression of a panel of oncogenic proteins (Bcl-2, Bcl-6, and c-Myc) and p53 with the overall survival of immunocompetent individuals with primary CNS DLBCL [ncbi , more ]and to study the expression profile of p73 in human normal tissues and the correlation between p73 expression and bladder cancer progression [ncbi , more ]. Chang Wei Feng et al. used EMD Millipore p53 antibody to study the correlation of expression of p53, VEGF, and iNOS and clinical features in gastric carcinogenesis [ncbi , more ] in 2002 and Setha Douc-Rasy et al. used EMD Millipore p53 antibody to study the role for the p73 gene in human neuroblastic tumors [ncbi , more ].
  • immunoprecipitationWassim Chatoo et al. utilized EMD Millipore p53 antibody to perform immunoprecipitation in order to illustrate that the Bmi1 functions on neurons oxidative metabolism are associated with repression of p53 pro-oxidant activity [ncbi , more ] in 2009 and Jennifer Hein et al. used EMD Millipore p53 antibody to study the effect of simian virus 40 large T antigen on genome integrity and DNA damage response [ncbi , more ]. Roman Kulikov et al. applied EMD Millipore p53 antibody to study the regulation of p53 abundance through glycogen synthase kinase 3-dependent phosphorylation of Mdm2 [ncbi , more ] in 2005 and Takayuki Hanamoto et al. used EMD Millipore p53 antibody to study the biological function of protein kinase A catalytic subunit beta [ncbi , more ]. In 2004, Yannick Doyon et al. applied EMD Millipore p53 antibody to investigate the function of NuA4 histone acetyltransferase (HAT) and demonstrate that NuA4 HAT complex is highly conserved in eukaryotes [ncbi , more ]. In 2003, Heng Yin Yang et al. employed EMD Millipore p53 antibody to study the effect of 14-3-3 on p53 and tumor growth [ncbi , more ]. In 2002, Thorsten Stiewe et al. employed EMD Millipore p53 antibody to study the role of TA-p73 expression for tumor formation [ncbi , more ]. In 2001, F Riva et al. used EMD Millipore p53 antibody to investigate the events in UV-induced DNA incision and proliferating cell nuclear antigen recruitment to repair sites [ncbi , more ].
  • western blotVeronique Marsaud et al. employed EMD Millipore p53 antibody to perform western blot in order to show the role of cyclin K and cyclin D1b in multiple myeloma [ncbi , more ] in 2010 and Laishram R Singh et al. used EMD Millipore p53 antibody to investigate the role of Hsp70 inducing agents in the treatment of genetic diseases [ncbi , more ]. EMD Millipore p53 antibody was applied in 2009 to perform western blot in order to study how to modulate gene expression and develop new drugs by short chain fatty acid (SCFA) hexosamine molecules [ncbi , more ], to investigate the role of endothelin systems in the regulation of physiologic renal growth and development [ncbi , more ], to perform Western blot in order to reveal oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6 [ncbi , more ], to demonstrate that the copy numbers of centriole and centrosome were regulated by Orc1 in human cells [ncbi , more ], to demonstrate that the deubiquitinating enzyme USP5 (isopeptidase T) can regulate the activity of p53 [ncbi , more ]and to perform western blot in order to show that autophagy is induced by stent-eluting drugs sirolimus and paclitaxel to suppress healing of the endothelium [ncbi , more ]. Kristin E Yates et al. applied EMD Millipore p53 antibody to perform western blot in order to show that p53-dependent premature senescence could be induced by repression of the SUMO-specific protease Senp1 in normal human fibroblasts [ncbi , more ] in 2008 and Sanjeev Shangary et al. used EMD Millipore p53 antibody to study the mechanism and effect of p53 activation by a potent and specific MDM2 antagonist (MI-43) in colon cancer [ncbi , more ]. In 2006, Michael A James et al. applied EMD Millipore p53 antibody to study the role for the effect of human papillomavirus Type 16 E6 on NF-kappaB activation and cIAP-2 expression in protecting from apoptosis in primary human airway epithelial cells [ncbi , more ]. EMD Millipore p53 antibody was used in 2005 to study the regulation of p53 abundance through glycogen synthase kinase 3-dependent phosphorylation of Mdm2 [ncbi , more ], to investigate the induction of DNA damage checkpoint signal transduction by herpes simplex virus [ncbi , more ], to investigate the effect of chloramphenicol-induced mitochondrial stress on p21 expression and cell apoptosis [ncbi , more ], to study the biological function of protein kinase A catalytic subunit beta [ncbi , more ], to study the prolongation of life span of human umbilical cord blood-derived mesenchymal stem cells (UCBMSCs) [ncbi , more ]and to study the interaction of DcR2 with p53 and the role for DcR2 in regulating chemosensitivity in human tumor cell lines [ncbi , more ]. In 2004, Zhihui Feng et al. employed EMD Millipore p53 antibody to study the induction of p53-dependent BRCA1 nuclear export by DNA damage [ncbi , more ]. EMD Millipore p53 antibody was employed in 2003 to study the role of mda-7 in the radiosensitivity of GBM cells in vitro and in vivo [ncbi , more ], to study the role of silenced p53 target gene snk/plk2 in leading to mitotik catastrophe in paclitaxel (taxol) exposed cells [ncbi , more ], to study the phosphatase MKP1 as a transcriptional target of p53 involved in cell cycle regulation [ncbi , more ], to study the molecular basis of p53 functional inactivation by the leukemic protein MLL-ELL [ncbi , more ]and to study the effect of 14-3-3 on p53 and tumor growth [ncbi , more ]. EMD Millipore p53 antibody was employed in 2002 to study the selective induction of apoptosis by synthetic retinoid CD437 in human lung cancer cells [ncbi , more ], to study the modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228 [ncbi , more ], to study interactions of the tumor suppressor protein p53 and DNA polymerase alpha-primase [ncbi , more ], to study the effect of p73beta on p57KIP2 expression [ncbi , more ], to study the role for LATS1 tumor suppressor in regulating G2/M transition and apoptosis in human cells [ncbi , more ], to study the role of TA-p73 expression for tumor formation [ncbi , more ], to study the interaction of p73 with c-Myc and MM1, a c-Myc-binding protein and the effect of it on the p73 function [ncbi , more ], to study the function of the heparin-binding domain and V region of fibronectin to regulate apoptosis by suppression of p53 and c-myc in human primary cells [ncbi , more ], to study the side effect of methylglyoxal in enhancing cisplatin-induced cytotoxicity by activating protein kinase Cdelta [ncbi , more ]and to study the induction of extracellular matrix-remodeling genes by the senescence-associated protein APA-1 [ncbi , more ]. EMD Millipore p53 antibody was utilized in 2001 to study the effect of the interaction between G2/M regulator 14-3-3delta and Bax on apoptosis [ncbi , more ], to study the role for the interaction of human SMG-1 with components of the mRNA surveillance complex in the regulation of nonsense-mediated mRNA decay [ncbi , more ]and to study the function of hSIR2 (SIRT1) as an NAD-dependent p53 deacetylase [ncbi , more ]. In 2000, S Nakamura et al. applied EMD Millipore p53 antibody to study the effect of multiple lysine mutations in the C-terminal domain of p53 on MDM2-dependent protein degradation and ubiquitination [ncbi , more ].
Life Technologies CorporationLife Technologies Corporation p53 product
  • immunohistochemistryIn 2009, Wei Zhou et al. employed Life Technologies Corporation p53 antibody to demonstrate whether overexpression of EMP3 in primary breast carcinoma is not associated with DNA methylation [ncbi , more ].
  • western blotIn 2008, Kwou Yeung Wu et al. utilized Life Technologies Corporation p53 antibody to investigate whether MMC induces cellular apoptosis in corneal endothelial cells [ncbi , more ].
BioLogoBioLogo p53 product
  • immunohistochemistryIn 2008, M Wenghoefer et al. used BioLogo p53 antibody to characterize proteins involved in cell cycle control [ncbi , more ].
AbD SerotecAbD Serotec p53 product
  • western blotIn 2006, Daniela Pasquali et al. employed AbD Serotec p53 antibody to study the expression of EG-VEGF/PK1 and PK2 and their receptors (PK-R1 and PK-R2) in human prostate and their involvement in cancer [ncbi , more ].
Thermo Scientific Pierce ProductsThermo Scientific Pierce Products p53 product
  • immunohistochemistryIn 2008, Zhenhua Song et al. utilized Thermo Scientific Pierce Products p53 antibody to investigate the expression of p16INK4a, p21WAF1/CIP1, p27KIP1, and p53 in human corneal endothelial cell (HCEC) senescence ex vivo at various donor ages [ncbi , more ]. In 2005, Xiao Dong Zhou et al. used Thermo Scientific Pierce Products p53 antibody to detect p53 in colon cancer tissues [ncbi , more ].
  • western blotIn 2006, Mariko Tomita et al. employed Thermo Scientific Pierce Products p53 antibody to study the effect of Jak-Stat pathway on cell growth of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells [ncbi , more ].
Beckman Coulter, Inc.Beckman Coulter, Inc. p53 product
  • immunohistochemistryIn 2009, Elke A Jarboe et al. employed Beckman Coulter, Inc. p53 antibody to perform immunohistochemistry in order to show that the p53 signature and endometrial glandular dysplasia often present at the beginning of serous intraepithelial carcinoma [ncbi , more ].
AbcamAbcam p53 product
  • immunohistochemistryIn 2009, Janine A Burns et al. employed Abcam p53 antibody to perform immunohistochemistry in order to study the function of the fixative in the immunohistochemical detection of phosphoproteins [ncbi , more ].
  • western blotIn 2010, Carlos Escande et al. used Abcam p53 antibody to investigate the role of DBC1 in the regulation of SIRT1 activity and high-fat diet induced liver steatosis in mice [ncbi , more ].
BD BiosciencesBD Biosciences p53 product
  • ChIP assayIn 2008, Leonie Smeenk et al. used BD Biosciences p53 antibody to identify p53 target genes using a genome-wide ChIP-on-chip study [ncbi , more ].
  • immunocytochemistryIn 2008, Leonie Smeenk et al. used BD Biosciences p53 antibody to identify p53 target genes using a genome-wide ChIP-on-chip study [ncbi , more ]. In 2002, Hisato Saitoh et al. utilized BD Biosciences p53 antibody to characterize the interaction between RanBP2 and Ubc9 [ncbi , more ].
  • western blotIn 2012, In Hye Lee et al. used BD Biosciences p53 antibody to perform western blot in order to show that p53-dependent cell proliferation and survival could be regulated by atg7 [ncbi , more ]. In 2008, Leonie Smeenk et al. used BD Biosciences p53 antibody to identify p53 target genes using a genome-wide ChIP-on-chip study [ncbi , more ]. In 2006, David Shackelford et al. utilized BD Biosciences p53 antibody to determine whether ATO could target AME and related oncoproteins [ncbi , more ]. In 2005, Hideshi Ishii et al. applied BD Biosciences p53 antibody to study the function of Frag1 protein in higher eukaryotes [ncbi , more ]. In 2004, Eva Pizzoferrato et al. applied BD Biosciences p53 antibody to study the role of IRF1 in human breast cancer cell death [ncbi , more ].
Abgent
  • western blotIn 2007, Lauren F Stevenson et al. employed Abgent p53 antibody to study the role of USP2a in the p53 pathway [ncbi , more ].
Sigma-AldrichSigma-Aldrich p53 product
  • ChIP assayIn 2008, E Lecona et al. utilized Sigma-Aldrich p53 antibody to demonstrate that annexin A1 promoter activity is controlled by a functional cooperation between p53 and factors binding to the proximal CCAAT box [ncbi , more ].
  • western blotIn 2009, Shiro Mizuno et al. applied Sigma-Aldrich p53 antibody to investigate the role of hypoxia in the regulation of human lung fibroblast proliferation [ncbi , more ]. In 2008, E Lecona et al. utilized Sigma-Aldrich p53 antibody to demonstrate that annexin A1 promoter activity is controlled by a functional cooperation between p53 and factors binding to the proximal CCAAT box [ncbi , more ].
DakoDako p53 product
  • immunohistochemistryIn 2010, Nagehan O Barisik et al. used Dako p53 antibody to perform immunohistochemistry in order to show that the relationship between expression and prognostic significance of Cox-2 and p-53 with Hodgkin lymphomas [ncbi , more ]. Dako p53 antibody was utilized in 2008 to identify biomarkers in ductal carcinoma in situ of the breast with microinvasion in paraffin sections from human tumor [ncbi , more ], to investigate the predictive value of clinical and biological markers for a pathological complete remission after a preoperative dose-dense regimen of doxorubicin and docetaxel, with or without tamoxifen, in primary operable breast cancer [ncbi , more ], to investigate the pathobiological behaviors of gastric mixed-type (MT) carcinomas and gastric carcinogenesis [ncbi , more ]and to perform immunohistochemistry in order to clarify that high CENP-F expression was the prognostic indicator of primary breast cancer [ncbi , more ]. Dako p53 antibody was applied in 2005 to study the association of the loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) with progression of human urothelial carcinomas [ncbi , more ], to investigate the distribution of p53 among different types and grades of human endometrial carcinomas [ncbi , more ]and to study the down-regulation of constitutive and UVB-induced COX-2 Levels by T-oligo treatment through p53- and NFB-dependent repression of the COX-2 promoter [ncbi , more ]. Dako p53 antibody was applied in 2004 to study the pathology of ovarian cancers in BRCA1 and BRCA2 carriers [ncbi , more ], to study the predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer [ncbi , more ], to study whether levels of ANX7 correlate with breast cancer progression and survival in paraffin sections from human tumor [ncbi , more ]and to detect p53 in normal lung, benign lesions, preinvasive lesions, low-grade tumors, and invasive lung carcinoma [ncbi , more ]. Dako p53 antibody was applied in 2003 to study the reduced dystroglycan expression in human breast and colon cancers and the possible association with tumor progression [ncbi , more ], to study the role of overexpression of macrophage migration inhibitory factor gene and protein for angiogenesis in glioblastoma multiforme [ncbi , more ]and to study the role for aberrant Wnt/ catenin pathway activation in idiopathic pulmonary fibrosis [ncbi , more ]. Dako p53 antibody was utilized in 2002 to study the association of p21 (WAF-1/CIP1) with progression to androgen-independent prostate cancer [ncbi , more ], to study translocation, deletion/amplification, and expression of HMGIC and MDM2 in a carcinoma ex pleomorphic adenoma [ncbi , more ]and to study the expression of cell-cycle-regulated proteins pRb2/p130, p107, p27kip1, p53, mdm-2, and Ki-67 in prostatic gland adenocarcinoma in paraffin sections from human tumor [ncbi , more ].
  • western blotDako p53 antibody was utilized in 2005 to study the lck degradation and refractory state in CD8+ cytotoxic T lymphocytes [ncbi , more ], to study the Np73-mediated transactivation of the BTG2TIS21/PC3 gene [ncbi , more ]and to study the down-regulation of constitutive and UVB-induced COX-2 Levels by T-oligo treatment through p53- and NFB-dependent repression of the COX-2 promoter [ncbi , more ]. In 2004, Antonio Marchini et al. employed Dako p53 antibody to study the role of shox in cell cycle, apoptosis, and human growth plate chondrocytes [ncbi , more ]. In 2003, Monique C A Duyndam et al. applied Dako p53 antibody to study the role of p38 kinase in hypoxia-inducible factor 1-independent induction of vascular endothelial growth factor expression by sodium arsenite [ncbi , more ]. F Riva et al. used Dako p53 antibody to investigate the events in UV-induced DNA incision and proliferating cell nuclear antigen recruitment to repair sites [ncbi , more ] in 2001 and J W Wilson et al. used Dako p53 antibody to investigate the correlation between Id helix-loop-helix proteins and p53 expression in colorectal adenocarcinoma (catalog: M7001) [ncbi , more ].
FREDERICK E DOMANN LAB
  • western blotIn 2008, Iman M Ahmad et al. utilized p53 antibody to demonstrate that inhibitors of glucose and hydroperoxide metabolism can be used in combination with Adp53 gene therapy to enhance cell killing in human prostate cancer cells [ncbi , more ].
NEO MARKERS INC
  • western blotIn 2009, Keiko Kawauchi et al. employed p53 antibody to perform western blot in order to prove that the catalytic activity of IKK modified with O-GlcNAc in p53-deficient cells is enhanced [ncbi , more ].
CEL SIGNALING TECHNOLOGY
  • western blotIn 2009, Alejo Efeyan et al. employed p53 antibody to suggest that ATM plays a role in oncogene-induced senescence or in p53-dependent tumor suppression [ncbi , more ].
Vector Laboratories
  • immunohistochemistryIn 2009, Erin R P Shull et al. employed Vector Laboratories p53 antibody to perform immunohistochemistry in order to show the different DNA damage signalings between A-T-like disease and Nijmegen breakage syndrome [ncbi , more ].
  • western blotIn 2010, Thomas G Fazzio et al. applied Vector Laboratories p53 antibody to investigate the mechanism of how the embryonic stem cells chromatin structure change was regulated by condensin complexes during mitotic progression [ncbi , more ].
Leica Microsystems
  • immunocytochemistryIn 2002, Olivier Kirsh et al. employed Leica Microsystems p53 antibody to study the role for SUMO E3 ligase RanBP2 in promoting modification of the HDAC4 deacetylase in human HeLa cells [ncbi , more ].
  • immunohistochemistryIn 2010, Jay P Reddy et al. applied Leica Microsystems p53 antibody to show the importance of protection of the ATM-mediated DDR-p53 signaling pathway for breast cancer prevention [ncbi , more ]. In 2009, Alejo Efeyan et al. used Leica Microsystems p53 antibody to incubate the tumor samples in order to suggest that ATM plays a role in oncogene-induced senescence or in p53-dependent tumor suppression [ncbi , more ]. In 2008, Seong Hyun Jeong et al. employed Leica Microsystems p53 antibody to evaluate the prognostic significance of apoptosis-related proteins p53, Bax, and galectin-3 in patients with non-small cell lung cancer (NSCLC) treated with surgical resection [ncbi , more ]. Leica Microsystems p53 antibody was used in 2003 to study the biological features of MLH1 expression during CDDP-based chemotherapy [ncbi , more ], to study the association between growth arrest DNA damage-inducible gene 45 expression and human hepatocellular carcinoma [ncbi , more ]and to study the cell cycle regulation in patients with IM at the GOJ [ncbi , more ]. In 2002, Toshiro Niki et al. employed Leica Microsystems p53 antibody to study the frequent co-Localization of cox-2 and laminin-5 2 chain at the invasive front of early-stage lung adenocarcinomas [ncbi , more ].
  • immunoprecipitationIn 2002, Maria Filippova et al. applied Leica Microsystems p53 antibody to study the interaction of HPV 16 E6 with TNF R1 in U2OS cells stably expressing HA-E6 [ncbi , more ].
  • western blotIn 2010, Hui Kuan Lin et al. employed Leica Microsystems p53 antibody to perform western blot in order to clarify that Skp2 involved in the p19Arf-p53 pathway independent cellular senescence [ncbi , more ]. In 2009, Deborah A Altomare et al. used Leica Microsystems p53 antibody to perform western blot in order to show that the loss of Faf1 resulted in aberrant NF-kB signaling and tumor progression [ncbi , more ]. In 2008, Konstantinos J Mavrakis et al. employed Leica Microsystems p53 antibody to detect p53 in mouse embryo fibroblasts (MEFs) [ncbi , more ]. In 2005, Andrew V Samuelson et al. utilized Leica Microsystems p53 antibody to study that p400 is required for E1A to promote apoptosis [ncbi , more ]. Paul A Jowsey et al. used Leica Microsystems p53 antibody to study the effect of human PTIP on ATM-mediated activation of p53 and cellular resistance to ionizing radiation [ncbi , more ] in 2004 and Evgenia K Mikaelsdottir et al. used Leica Microsystems p53 antibody to study the expression of the mutated BRCA2 gene in BRCA2 999del5 heterozygous cells and the functional consequences of BRCA2 999del5 at the cellular level [ncbi , more ].
Wako Chemicals USA
  • immunohistochemistryIn 2002, Katsuhiro Uzawa et al. used Wako Chemicals USA p53 antibody to study the high prevalence of decreased expression of KAI1 metastasis suppressor in human oral carcinogenesis [ncbi , more ].
Roche Applied Science
  • ELISAIn 2002, Maria Filippova et al. utilized Roche Applied Science p53 antibody to detect the level of p53 in U2OS cells transfected with either sense or antisense versions of epitope-tagged HA-E6 [ncbi , more ].
Figure
Santa Cruz monoclonal anti-p53 was used to perform western blot in order to show that global sumoylation and Pias3 stabilization could be regulated by nitric oxide.
p53 antibody western blot Santa Cruz Biotechnology
HEK293 cells were transfected with the indicated plasmids, treated with H2O2 (for 1h) or GSNO (for 4 h), lysed in Laemmli buffer, and immunoblotted with p53 or actin.
Jing Qu et al. (2007). "Nitric oxide destabilizes Pias3 and regulates sumoylation".PMID 17987106
Articles Reviewed
  1. Jeremy E Purvis et al. (2012). "p53 dynamics control cell fate".PMID 22700930
  2. In Hye Lee et al. (2012). "Atg7 modulates p53 activity to regulate cell cycle and survival during metabolic stress".PMID 22499945
  3. Aniek Janssen et al. (2011). "Chromosome segregation errors as a cause of DNA damage and structural chromosome aberrations".PMID 21960636
  4. Linwei Li et al. (2010). "The candidate tumor suppressor gene ECRG4 inhibits cancer cells migration and invasion in esophageal carcinoma".PMID 20937111
  5. David Bungard et al. (2010). "Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation".PMID 20647423
  6. Veronique Marsaud et al. (2010). "Cyclin K and cyclin D1b are oncogenic in myeloma cells".PMID 20459741
  7. Nagehan O Barisik et al. (2010). "Expression and prognostic significance of Cox-2 and p-53 in Hodgkin lymphomas: a retrospective study".PMID 20346139
  8. Andrea Lunardi et al. (2010). "A genome-scale protein interaction profile of Drosophila p53 uncovers additional nodes of the human p53 network".PMID 20308539
  9. Hui Kuan Lin et al. (2010). "Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence".PMID 20237562
  10. Thomas G Fazzio et al. (2010). "Condensin complexes regulate mitotic progression and interphase chromatin structure in embryonic stem cells".PMID 20176923
  11. Jay P Reddy et al. (2010). "Defining the ATM-mediated barrier to tumorigenesis in somatic mammary cells following ErbB2 activation".PMID 20133707
  12. Carlos Escande et al. (2010). "Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice".PMID 20071779
  13. Laishram R Singh et al. (2010). "Activation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70".PMID 20066033
  14. Shinako Araki et al. (2010). "TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer".PMID 19955655
  15. Ying Geng et al. (2010). "Cytoplasmic p53 and activated Bax regulate p53-dependent, transcription-independent neural precursor cell apoptosis".PMID 19901272
  16. Shin Ichiro Hayashi et al. (2009). "The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy".PMID 19815708
  17. Lisa S Chen et al. (2009). "Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells".PMID 19734450
  18. E Giaime et al. (2010). "Loss of function of DJ-1 triggered by Parkinson's disease-associated mutation is due to proteolytic resistance to caspase-6".PMID 19680261
  19. Hailing Cheng et al. (2009). "SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis".PMID 19622832
  20. Renyuan Zhou et al. (2010). "Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53".PMID 19609950
  21. Wei Qin Jiang et al. (2009). "Induction of alternative lengthening of telomeres-associated PML bodies by p53/p21 requires HP1 proteins".PMID 19468068
  22. Alejo Efeyan et al. (2009). "Limited role of murine ATM in oncogene-induced senescence and p53-dependent tumor suppression".PMID 19421407
  23. Bin Zhang et al. (2009). "Dosage effects of cohesin regulatory factor PDS5 on mammalian development: implications for cohesinopathies".PMID 19412548
  24. Noha Elmouelhi et al. (2009). "Hexosamine template. A platform for modulating gene expression and for sugar-based drug discovery".PMID 19326913
  25. Rene Rodriguez et al. (2009). "Loss of p53 induces tumorigenesis in p21-deficient mesenchymal stem cells".PMID 19308294
  26. Kee Hwan Yoo et al. (2009). "Endothelin A receptor blockade influences apoptosis and cellular proliferation in the developing rat kidney".PMID 19270827
  27. Wei Zhou et al. (2009). "EMP3 overexpression in primary breast carcinomas is not associated with epigenetic aberrations".PMID 19270820
  28. Shiro Mizuno et al. (2009). "Hypoxia regulates human lung fibroblast proliferation via p53-dependent and -independent pathways".PMID 19267931
  29. Xiaohong Wang et al. (2009). "Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6".PMID 19258450
  30. Jayasree S Nair et al. (2009). "Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780".PMID 19225156
  31. Surojit Sur et al. (2009). "A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53".PMID 19225112
  32. Deborah A Altomare et al. (2009). "Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice".PMID 19223589
  33. Keiko Kawauchi et al. (2009). "Loss of p53 enhances catalytic activity of IKKbeta through O-linked beta-N-acetyl glucosamine modification".PMID 19202066
  34. Adriana S Hemerly et al. (2009). "Orc1 controls centriole and centrosome copy number in human cells".PMID 19197067
  35. Erin R P Shull et al. (2009). "Differential DNA damage signaling accounts for distinct neural apoptotic responses in ATLD and NBS".PMID 19171781
  36. Elke A Jarboe et al. (2009). "Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma".PMID 19151662
  37. Wassim Chatoo et al. (2009). "The polycomb group gene Bmi1 regulates antioxidant defenses in neurons by repressing p53 pro-oxidant activity".PMID 19144853
  38. Eleonora Forte et al. (2009). "MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival".PMID 19144715
  39. Ivan Topisirovic et al. (2009). "Stability of eukaryotic translation initiation factor 4E mRNA is regulated by HuR, and this activity is dysregulated in cancer".PMID 19114552
  40. Shigeto Ueda et al. (2008). "Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer".PMID 19102762
  41. Saurabh Dayal et al. (2009). "Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53".PMID 19098288
  42. Yong Chul Kim et al. (2009). "Activation of ATM depends on chromatin interactions occurring before induction of DNA damage".PMID 19079244
  43. Ananta Gurung et al. (2009). "Beta-catenin is a mediator of the response of fibroblasts to irradiation".PMID 19036807
  44. Janine A Burns et al. (2009). "Choice of fixative is crucial to successful immunohistochemical detection of phosphoproteins in paraffin-embedded tumor tissues".PMID 19001637
  45. Vladimir L Gabai et al. (2009). "Heat shock protein Hsp72 controls oncogene-induced senescence pathways in cancer cells".PMID 19001088
  46. Omedul Islam et al. (2009). "Interleukin-6 and neural stem cells: more than gliogenesis".PMID 18971377
  47. Stéphanie Solier et al. (2009). "Death receptor-induced activation of the Chk2- and histone H2AX-associated DNA damage response pathways".PMID 18955500
  48. Jennifer Hein et al. (2009). "Simian virus 40 large T antigen disrupts genome integrity and activates a DNA damage response via Bub1 binding".PMID 18922873
  49. M Wenghoefer et al. (2008). "Nuclear hBD-1 accumulation in malignant salivary gland tumours".PMID 18840281
  50. Yasuhiro Okumura et al. (2008). "Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion".PMID 18837981
  51. Kwou Yeung Wu et al. (2008). "Mechanism of mitomycin-induced apoptosis in cultured corneal endothelial cells".PMID 18806879
  52. Seong Hyun Jeong et al. (2008). "Low expression of Bax predicts poor prognosis in resected non-small cell lung cancer patients with non-squamous histology".PMID 18772168
  53. Konstantinos J Mavrakis et al. (2008). "Tumorigenic activity and therapeutic inhibition of Rheb GTPase".PMID 18708578
  54. Jennifer M Rosenbluth et al. (2008). "A gene signature-based approach identifies mTOR as a regulator of p73".PMID 18678646
  55. Kristin E Yates et al. (2008). "Repression of the SUMO-specific protease Senp1 induces p53-dependent premature senescence in normal human fibroblasts".PMID 18616636
  56. Sanjeev Shangary et al. (2008). "Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer".PMID 18566224
  57. Jean Luc Perfettini et al. (2008). "Critical involvement of the ATM-dependent DNA damage response in the apoptotic demise of HIV-1-elicited syncytia".PMID 18560558
  58. Jung Yoon Park et al. (2008). "Homeostatic imbalance between apoptosis and cell renewal in the liver of premature aging Xpd mice".PMID 18545656
  59. E Lecona et al. (2008). "Upregulation of annexin A1 expression by butyrate in human colon adenocarcinoma cells: role of p53, NF-Y, and p38 mitogen-activated protein kinase".PMID 18541673
  60. Li Zeng et al. (2008). "Saturated fatty acids modulate cell response to DNA damage: implication for their role in tumorigenesis".PMID 18523653
  61. Leonie Smeenk et al. (2008). "Characterization of genome-wide p53-binding sites upon stress response".PMID 18474530
  62. Chunrong Yu et al. (2008). "Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells".PMID 18445700
  63. Suchismita Panda et al. (2008). "Modification of the ATM/ATR directed DNA damage response state with aging and long after hepatocyte senescence induction in vivo".PMID 18440596
  64. Nobuyuki Kikuno et al. (2008). "Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells".PMID 18431742
  65. Gunter von Minckwitz et al. (2008). "Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast".PMID 18380893
  66. Zhenhua Song et al. (2008). "Expression of senescence-related genes in human corneal endothelial cells".PMID 18334933
  67. Hua Chuan Zheng et al. (2008). "Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas".PMID 18266006
  68. Iman M Ahmad et al. (2008). "2-Deoxyglucose combined with wild-type p53 overexpression enhances cytotoxicity in human prostate cancer cells via oxidative stress".PMID 18155176
  69. Jie Zhou et al. (2008). "The antiapoptotic role of pregnane X receptor in human colon cancer cells".PMID 18096695
  70. Jin Hee Lee et al. (2008). "Frequent epigenetic inactivation of hSRBC in gastric cancer and its implication in attenuated p53 response to stresses".PMID 18059034
  71. Jing Qu et al. (2007). "Nitric oxide destabilizes Pias3 and regulates sumoylation".PMID 17987106
  72. Min Wang et al. (2007). "BAF53 interacts with p53 and functions in p53-mediated p21-gene transcription".PMID 17878219
  73. Lukas M Orre et al. (2007). "Up-regulation, modification, and translocation of S100A6 induced by exposure to ionizing radiation revealed by proteomics profiling".PMID 17785350
  74. Douglas M Iddings et al. (2007). "Association of angiogenesis markers with lymph node metastasis in early colorectal cancer".PMID 17709727
  75. Marco A Napolitano et al. (2007). "Brg1 chromatin remodeling factor is involved in cell growth arrest, apoptosis and senescence of rat mesenchymal stem cells".PMID 17666433
  76. Thérèse Rachell Theodoro et al. (2007). "Heparanase expression in circulating lymphocytes of breast cancer patients depends on the presence of the primary tumor and/or systemic metastasis".PMID 17603633
  77. Yunli Zhou et al. (2007). "Activation of p53 by MEG3 non-coding RNA".PMID 17569660
  78. Pabbisetty Sudheer Kumar et al. (2007). "Differential expression and role of p21cip/waf1 and p27kip1 in TNF-alpha-induced inhibition of proliferation in human glioma cells".PMID 17565690
  79. Juan M Funes et al. (2007). "Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production".PMID 17384149
  80. Ana Cuadrado et al. (2007). "A new p38 MAP kinase-regulated transcriptional coactivator that stimulates p53-dependent apoptosis".PMID 17380123
  81. Lauren F Stevenson et al. (2007). "The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2".PMID 17290220
  82. David Shackelford et al. (2006). "Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide".PMID 17145882
  83. Laura M Rozan et al. (2006). "Identification and characterization of proteins interacting with Traf4, an enigmatic p53 target".PMID 16969126
  84. Daniela Pasquali et al. (2006). "The endocrine-gland-derived vascular endothelial growth factor (EG-VEGF)/prokineticin 1 and 2 and receptor expression in human prostate: Up-regulation of EG-VEGF/prokineticin 1 with malignancy".PMID 16763065
  85. Michael A James et al. (2006). "Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner".PMID 16699010
  86. Matthias Woenckhaus et al. (2007). "Nuclear and cytoplasmic Maspin expression in primary non-small cell lung cancer".PMID 16698957
  87. Mariko Tomita et al. (2006). "Inhibition of constitutively active Jak-Stat pathway suppresses cell growth of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells".PMID 16603085
  88. Jianwei Ren et al. (2006). "FAT10 plays a role in the regulation of chromosomal stability".PMID 16495226
  89. Sylwia Ammoun et al. (2006). "G-protein-coupled OX1 orexin/hcrtr-1 hypocretin receptors induce caspase-dependent and -independent cell death through p38 mitogen-/stress-activated protein kinase".PMID 16282319
  90. Xiangguo Liu et al. (2005). "Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity".PMID 16230375
  91. Roman Kulikov et al. (2005). "Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance".PMID 16055726
  92. Anja Duursma et al. (2005). "p53-Dependent regulation of Cdc6 protein stability controls cellular proliferation".PMID 16055707
  93. Vaneeta Marwaha et al. (2005). "T-oligo treatment decreases constitutive and UVB-induced COX-2 levels through p53- and NFkappaB-dependent repression of the COX-2 promoter".PMID 16046401
  94. Hideshi Ishii et al. (2005). "Frag1, a homolog of alternative replication factor C subunits, links replication stress surveillance with apoptosis".PMID 15983387
  95. Noriko Shirata et al. (2005). "Activation of ataxia telangiectasia-mutated DNA damage checkpoint signal transduction elicited by herpes simplex virus infection".PMID 15964848
  96. Shashirekha Shetty et al. (2005). "Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1".PMID 15964798
  97. Jean Francois Lavoie et al. (2005). "TrkA induces apoptosis of neuroblastoma cells and does so via a p53-dependent mechanism".PMID 15961390
  98. Michael Uhlin et al. (2005). "Regulation of lck degradation and refractory state in CD8+ cytotoxic T lymphocytes".PMID 15958529
  99. Yuichi J Machida et al. (2005). "Acute reduction of an origin recognition complex (ORC) subunit in human cells reveals a requirement of ORC for Cdk2 activation".PMID 15944161
  100. Andrea Mueller et al. (2005). "The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity".PMID 15941720
  101. Armando Rivera et al. (2005). "The p53-induced gene-6 (proline oxidase) mediates apoptosis through a calcineurin-dependent pathway".PMID 15914462
  102. Ching Hao Li et al. (2005). "Chloramphenicol-induced mitochondrial stress increases p21 expression and prevents cell apoptosis through a p21-dependent pathway".PMID 15905168
  103. Tetsuo Mashima et al. (2005). "p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target".PMID 15900046
  104. Lindsey D Mayo et al. (2005). "Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified".PMID 15843377
  105. Xiao Dong Zhou et al. (2005). "Expression of cellular FLICE-inhibitory protein and its association with p53 mutation in colon cancer".PMID 15832422
  106. Mark W Jackson et al. (2005). "p130/p107/p105Rb-dependent transcriptional repression during DNA-damage-induced cell-cycle exit at G2".PMID 15827088
  107. David Goldschneider et al. (2005). "The neurogene BTG2TIS21/PC3 is transactivated by DeltaNp73alpha via p53 specifically in neuroblastoma cells".PMID 15741235
  108. Andrew V Samuelson et al. (2005). "p400 is required for E1A to promote apoptosis".PMID 15741165
  109. Gita Ohlsson et al. (2005). "Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas".PMID 15734831
  110. Takayuki Hanamoto et al. (2005). "Identification of protein kinase A catalytic subunit beta as a novel binding partner of p73 and regulation of p73 function".PMID 15723830
  111. Masanori Terai et al. (2005). "Immortalization of human fetal cells: the life span of umbilical cord blood-derived cells can be prolonged without manipulating p16INK4a/RB braking pathway".PMID 15647378
  112. Eva Pizzoferrato et al. (2004). "Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin".PMID 15548708
  113. Paul A Jowsey et al. (2004). "Human PTIP facilitates ATM-mediated activation of p53 and promotes cellular resistance to ionizing radiation".PMID 15456759
  114. Soo Jung Park et al. (2004). "Taxol induces caspase-10-dependent apoptosis".PMID 15452117
  115. Yunfei Ding et al. (2005). "NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer".PMID 15358636
  116. Joshua Silverman et al. (2004). "Human Rif1, ortholog of a yeast telomeric protein, is regulated by ATM and 53BP1 and functions in the S-phase checkpoint".PMID 15342490
  117. Barbara I Oberschmid et al. (2004). "Distinct secreted Frizzled receptor protein 1 staining pattern in patients with hyperplastic polyposis coli syndrome".PMID 15335268
  118. Jian Zhong Qin et al. (2004). "p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas".PMID 15299072
  119. Debra L Bemis et al. (2004). "A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo".PMID 15297432
  120. Dhananjay A Chitale et al. (2005). "Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray".PMID 15272278
  121. Evgenia K Mikaelsdottir et al. (2004). "The Icelandic founder mutation BRCA2 999del5: analysis of expression".PMID 15217494
  122. Véronique Gire et al. (2004). "DNA damage checkpoint kinase Chk2 triggers replicative senescence".PMID 15192702
  123. Sung Kwon Moon et al. (2004). "Disialoganglioside (GD3) synthase gene expression suppresses vascular smooth muscle cell responses via the inhibition of ERK1/2 phosphorylation, cell cycle progression, and matrix metalloproteinase-9 expression".PMID 15175338
  124. Antonio Marchini et al. (2004). "The short stature homeodomain protein SHOX induces cellular growth arrest and apoptosis and is expressed in human growth plate chondrocytes".PMID 15145945
  125. Julien Mazieres et al. (2004). "Loss of RhoB expression in human lung cancer progression".PMID 15102679
  126. Zhihui Feng et al. (2004). "DNA damage induces p53-dependent BRCA1 nuclear export".PMID 15087457
  127. Sunil R Lakhani et al. (2004). "Pathology of ovarian cancers in BRCA1 and BRCA2 carriers".PMID 15073127
  128. Jian Liu Wang et al. (2004). "Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer".PMID 15073118
  129. Meera Srivastava et al. (2004). "Prognostic impact of ANX7-GTPase in metastatic and HER2-negative breast cancer patients".PMID 15073110
  130. Yannick Doyon et al. (2004). "Structural and functional conservation of the NuA4 histone acetyltransferase complex from yeast to humans".PMID 14966270
  131. Shinobu Honda et al. (2004). "Activation of m-calpain is required for chromosome alignment on the metaphase plate during mitosis".PMID 14688278
  132. Pere Puig et al. (2003). "p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer".PMID 14654547
  133. Hariklia Gakiopoulou et al. (2003). "Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas".PMID 14654538
  134. N J Trudgill et al. (2003). "Cell cycle regulation in patients with intestinal metaplasia at the gastro-oesophageal junction".PMID 14645692
  135. Salvatore Cortellino et al. (2003). "The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity".PMID 14614141
  136. Lisa Y Zhao et al. (2003). "Adenovirus E1B 55-kilodalton oncoprotein binds to Daxx and eliminates enhancement of p53-dependent transcription by Daxx".PMID 14557665
  137. Kentaro Kishi et al. (2003). "Reduced MLH1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers".PMID 14555508
  138. Heng Yin Yang et al. (2003). "14-3-3 sigma positively regulates p53 and suppresses tumor growth".PMID 14517281
  139. Stefanie Galban et al. (2003). "Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells".PMID 14517280
  140. Gina Fusaro et al. (2003). "Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling".PMID 14500729
  141. Laura Leung et al. (2003). "Deficiency of the Nrf1 and Nrf2 transcription factors results in early embryonic lethality and severe oxidative stress".PMID 12968018
  142. Adly Yacoub et al. (2003). "Melanoma differentiation-associated 7 (interleukin 24) inhibits growth and enhances radiosensitivity of glioma cells in vitro and in vivo".PMID 12960112
  143. Timothy F Burns et al. (2003). "Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells".PMID 12897130
  144. Maoxiang Li et al. (2003). "The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation".PMID 12890671
  145. Krystyna Mazan-Mamczarz et al. (2003). "RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation".PMID 12821781
  146. Igal Louria-Hayon et al. (2003). "The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation".PMID 12810724
  147. Sonia Rocha et al. (2003). "p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1".PMID 12808109
  148. Soichi Tsutsumi et al. (2003). "Regulation of cell proliferation by autocrine motility factor/phosphoglucose isomerase signaling".PMID 12783864
  149. Dmitri Wiederschain et al. (2003). "Molecular basis of p53 functional inactivation by the leukemic protein MLL-ELL".PMID 12773566
  150. Weihua Qiu et al. (2003). "Down-regulation of growth arrest DNA damage-inducible gene 45beta expression is associated with human hepatocellular carcinoma".PMID 12759252
  151. A M Stark et al. (2003). "p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme".PMID 12754350
  152. Anna A Sablina et al. (2003). "Tumor suppressor p53 and its homologue p73alpha affect cell migration".PMID 12750388
  153. Martin Monte et al. (2003). "The cell cycle-regulated protein human GTSE-1 controls DNA damage-induced apoptosis by affecting p53 function".PMID 12750368
  154. Dong Wook Kim et al. (2003). "RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1".PMID 12738763
  155. Marco Chilosi et al. (2003). "Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis".PMID 12707032
  156. Hesham M Amin et al. (2003). "Characterization of 4 mantle cell lymphoma cell lines".PMID 12683869
  157. Ursula G B Haider et al. (2003). "Resveratrol increases serine15-phosphorylated but transcriptionally impaired p53 and induces a reversible DNA replication block in serum-activated vascular smooth muscle cells".PMID 12644594
  158. Daniel J Freeman et al. (2003). "PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms".PMID 12620407
  159. Delin Chen et al. (2003). "Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function".PMID 12606552
  160. Alessandro Sgambato et al. (2003). "Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression".PMID 12598319
  161. Chung Che Chang et al. (2003). "Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals".PMID 12562237
  162. Steve A Maxwell et al. (2003). "Proline oxidase induces apoptosis in tumor cells, and its expression is frequently absent or reduced in renal carcinomas".PMID 12514185
  163. J E Cleaver et al. (2002). "Polymerase eta and p53 jointly regulate cell survival, apoptosis and Mre11 recombination during S phase checkpoint arrest after UV irradiation".PMID 12509296
  164. Michael Bacher et al. (2003). "Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme".PMID 12507885
  165. Monique C A Duyndam et al. (2003). "Evidence for a role of p38 kinase in hypoxia-inducible factor 1-independent induction of vascular endothelial growth factor expression by sodium arsenite".PMID 12482858
  166. Chuangui Wang et al. (2003). "Phosphorylation and hsp90 binding mediate heat shock stabilization of p53".PMID 12427754
  167. David M Keller et al. (2002). "p53 serine 392 phosphorylation increases after UV through induction of the assembly of the CK2.hSPT16.SSRP1 complex".PMID 12393879
  168. Jennifer A Benanti et al. (2002). "Induction of extracellular matrix-remodeling genes by the senescence-associated protein APA-1".PMID 12370286
  169. Yaron Daniely et al. (2002). "Stress-dependent nucleolin mobilization mediated by p53-nucleolin complex formation".PMID 12138209
  170. Mihail S Iordanov et al. (2002). "The UV (Ribotoxic) stress response of human keratinocytes involves the unexpected uncoupling of the Ras-extracellular signal-regulated kinase signaling cascade from the activated epidermal growth factor receptor".PMID 12101233
  171. Mark Wunderlich et al. (2002). "Mdm2 inhibition of p53 induces E2F1 transactivation via p21".PMID 12080472
  172. Pier Paolo Claudio et al. (2002). "Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma".PMID 12060621
  173. Hanqian Carlson et al. (2002). "Tbx3 impinges on the p53 pathway to suppress apoptosis, facilitate cell transformation and block myogenic differentiation".PMID 12032820
  174. Olivier Kirsh et al. (2002). "The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase".PMID 12032081
  175. Chang Wei Feng et al. (2002). "Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features".PMID 11978184
  176. Junko Tsubaki et al. (2002). "Differential activation of the IGF binding protein-3 promoter by butyrate in prostate cancer cells".PMID 11956160
  177. Shi Yong Sun et al. (2002). "The synthetic retinoid CD437 selectively induces apoptosis in human lung cancer cells while sparing normal human lung epithelial cells".PMID 11956107
  178. Ethan A Kohn et al. (2002). "Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation".PMID 11953432
  179. Maria Filippova et al. (2002). "The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis".PMID 11934887
  180. Xiaodan Yu et al. (2002). "Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228".PMID 11929951
  181. Christian Melle et al. (2002). "Physical and functional interactions of the tumor suppressor protein p53 and DNA polymerase alpha-primase".PMID 11917009
  182. Katsuhiro Uzawa et al. (2002). "High prevalence of decreased expression of KAI1 metastasis suppressor in human oral carcinogenesis".PMID 11895916
  183. Karim Fizazi et al. (2002). "The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer".PMID 11895908
  184. Eva Balint et al. (2002). "Induction of p57(KIP2) expression by p73beta".PMID 11891335
  185. Toshiro Niki et al. (2002). "Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas".PMID 11891209
  186. Hong Xia et al. (2002). "LATS1 tumor suppressor regulates G2/M transition and apoptosis".PMID 11850843
  187. Thorsten Stiewe et al. (2002). "Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis".PMID 11844800
  188. Ken ichi Watanabe et al. (2002). "Physical interaction of p73 with c-Myc and MM1, a c-Myc-binding protein, and modulation of the p73 function".PMID 11844794
  189. Setha Douc-Rasy et al. (2002). "DeltaN-p73alpha accumulates in human neuroblastic tumors".PMID 11839584
  190. Eva Roijer et al. (2002). "Translocation, deletion/amplification, and expression of HMGIC and MDM2 in a carcinoma ex pleomorphic adenoma".PMID 11839563
  191. Virginia Urquidi et al. (2002). "Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis".PMID 11801541
  192. Fei Su et al. (2002). "WISP-1 attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase".PMID 11782444
  193. Yvonne L Kapila et al. (2002). "The heparin-binding domain and V region of fibronectin regulate apoptosis by suppression of p53 and c-myc in human primary cells".PMID 11751853
  194. F Riva et al. (2001). "UV-induced DNA incision and proliferating cell nuclear antigen recruitment to repair sites occur independently of p53-replication protein A interaction in p53 wild type and mutant ovarian carcinoma cells".PMID 11751427
  195. J W Wilson et al. (2001). "Expression of Id helix-loop-helix proteins in colorectal adenocarcinoma correlates with p53 expression and mitotic index".PMID 11751402
  196. Hisato Saitoh et al. (2002). "Perturbation of SUMOlation enzyme Ubc9 by distinct domain within nucleoporin RanBP2/Nup358".PMID 11709548
  197. Jonathan P Godbout et al. (2002). "Methylglyoxal enhances cisplatin-induced cytotoxicity by activating protein kinase Cdelta".PMID 11707430
  198. Keitaro Tsuji et al. (2002). "Differential effect of ik3-1/cables on p53- and p73-induced cell death".PMID 11706030
  199. Philip J Young et al. (2002). "A direct interaction between the survival motor neuron protein and p53 and its relationship to spinal muscular atrophy".PMID 11704667
  200. H Vaziri et al. (2001). "hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase".PMID 11672523
  201. M Castedo et al. (2001). "Human immunodeficiency virus 1 envelope glycoprotein complex-induced apoptosis involves mammalian target of rapamycin/FKBP12-rapamycin-associated protein-mediated p53 phosphorylation".PMID 11602639
  202. T Samuel et al. (2001). "The G2/M regulator 14-3-3sigma prevents apoptosis through sequestration of Bax".PMID 11574543
  203. A Yamashita et al. (2001). "Human SMG-1, a novel phosphatidylinositol 3-kinase-related protein kinase, associates with components of the mRNA surveillance complex and is involved in the regulation of nonsense-mediated mRNA decay".PMID 11544179
  204. Y Hirose et al. (2001). "Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells".PMID 11479224
  205. S Xie et al. (2001). "Reactive oxygen species-induced phosphorylation of p53 on serine 20 is mediated in part by polo-like kinase-3".PMID 11447225
  206. J Wang et al. (2001). "Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression".PMID 11259653
  207. T Imamura et al. (2001). "Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein".PMID 11106654
  208. S Nakamura et al. (2000). "Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination".PMID 11094089
  209. D L Persons et al. (2000). "Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin".PMID 10958792
  210. M Pastorcic et al. (2000). "Regulation of transcription of the human presenilin-1 gene by ets transcription factors and the p53 protooncogene".PMID 10942770